Galapagos announces that BioFocus has signed an integrated drug discovery collaboration with Boehringer Ingelheim

Galapagos (Euronext: GLPG) announced today
that   its  BioFocus  subsidiary  signed  a  new  collaboration  agreement  with
Boehringer Ingelheim.  Under the terms of the agreement, BioFocus will apply its
extensive  drug discovery  services to  an undisclosed  target within Boehringer
Ingelheim's drug discovery portfolio.

David  Smith, CEO  Services commented,  "We are  delighted to  have secured this
contract  with Boehringer Ingelheim,  one of the  world's leading research-based
pharmaceutical   companies  and  a  new  integrated  drug  discovery  client  to
BioFocus.  It is testament to the strength and depth of BioFocus' drug discovery
capabilities and expertise in this particular gene family."

About BioFocus
BioFocus  provides  integrated  drug  discovery  that delivers pre-clinical drug
candidates    in   all   therapeutic   areas   with   strong   capabilities   in
neurodegenerative   diseases,  inflammatory  diseases  and  rare  and  neglected
diseases.   BioFocus has advanced and  comprehensive drug discovery capabilities
that  are applied to  client projects to  deliver targets, hits,  leads and pre-
clinical  candidates.  The company employs  over 150 exceptionally qualified and
industry  experienced  scientists  at  its  research  centers  in the UK and the
Netherlands.   Since its foundation in  1997, BioFocus has produced high quality
data  for its  clients, assured  by ISO9001  qualification, validated by regular
independent  inspection of all BioFocus  research centers. For more information,
visit us at Twitter, LinkedIn, Google+ and at www.biofocus.com.

About Boehringer Ingelheim

The  Boehringer Ingelheim group is one  of the world's 20 leading pharmaceutical
companies.  Headquartered in Ingelheim, Germany,  it operates globally with 140
affiliates  and more  than 46,000 employees.  Since it  was founded in 1885, the
family-owned   company   has   been   committed   to   researching,  developing,
manufacturing  and  marketing  novel  medications  of high therapeutic value for
human and veterinary medicine.

Social   responsibility   is   a   central  element  of  Boehringer  Ingelheim's
culture.   Involvement in social  projects, caring for  employees and their
families,   and  providing  equal  opportunities  for  all  employees  form  the
foundation  of the global operations. Mutual cooperation and respect, as well as
environmental  protection  and  sustainability  are  intrinsic factors in all of
Boehringer Ingelheim's endeavors.

In  2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro, of
which 22.5% of the net sales from our Prescription Medicine business is invested
into research and development. For more information please visit www.boehringer-
ingelheim.com

About Galapagos
Galapagos  (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with  a large pipeline  of five Phase2  (two led by  GSK), one Phase 1, six pre-
clinical,  and more  than 20 discovery  small-molecule and  antibody programs in
cystic   fibrosis,  inflammation,  antibiotics,  metabolic  disease,  and  other
indications.
GLPG0634  is an orally-available, selective inhibitor  of JAK1 for the treatment
of  rheumatoid arthritis and potentially  other inflammatory diseases, currently
in  Phase  2B studies  in  RA  and  about  to  enter  Phase 2 studies in Crohn's
disease.   AbbVie  and  Galapagos  signed  a worldwide license agreement whereby
AbbVie  will be responsible for  further development and commercialization after
Phase  2B.  Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly
GLPG0778,  in-licensed  by  GlaxoSmithKline  in  2012) in  Phase  2 in lupus and
psoriasis, studies led by GSK.  GLPG0187 is a novel integrin receptor antagonist
currently  in a  Phase 1B patient  study in  metastasis.  GLPG0974  is the first
inhibitor  of FFA2  to be  evaluated clinically  for the  treatment of IBD; this
program  is currently in a Proof of Concept Phase 2 study.  GLPG1205 is a first-
in-class  molecule that  targets inflammatory  disorders and  is currently  in a
First-in-Human Phase 1 study.
The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta and
Fidelta,  has  800 employees  and  operates  facilities  in five countries, with
global headquarters in Mechelen, Belgium.  Further information at: www.glpg.com

More information:

Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: [phone]
[e-mail]


This   release   may  contain  forward-looking  statements,  including,  without
limitation,   statements   containing   the   words  "believes,"  "anticipates,"
"expects,"  "intends,"  "plans,"  "seeks,"  "estimates," "may," "will," "could,"
"stands  to," and  "continues," as  well as  similar expressions.  Such forward-
looking  statements may involve known and unknown risks, uncertainties and other
factors  which might cause the  actual results, financial condition, performance
or  achievements of Galapagos,  or industry results,  to be materially different
from  any  historic  or  future  results,  financial  conditions, performance or
achievements  expressed or  implied by  such forward-looking  statements.  Given
these  uncertainties, the reader is  advised not to place  any undue reliance on
such forward-looking statements.  These forward-looking statements speak only as
of  the date of publication of this document.  Galapagos expressly disclaims any
obligation  to update  any such  forward-looking statements  in this document to
reflect  any change  in its  expectations with  regard thereto  or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.



[HUG#1744403]